What is Bi-Specific 3rd Generation Chimeric Antigen Receptor T (CAR-T) cells? Bi-Specific 3rd Generation CAR T therapy is a revolutionary advancement in cellular immunotherapy, primarily used to treat ...

A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in Canada for adults with an ultra-rare form of the disease. Paula ...

Despite its promise, autologous chimeric antigen receptor T-cell (CAR T-cell) therapy faces several challenges, including limited accessibility, high costs and manufacturing bottlenecks. Allogeneic ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech Pharmaceuticals is on the verge of making its commercial debut. The FDA last week ...

New CAR-T cell therapy shows promise for hard-to-treat cancers Date: March 10, 2025 Source: University of Colorado Anschutz Medical Campus Summary: Researchers have successfully developed a ...

"When you look back, it's easy to see how revolutionary CAR-T cells have been. But, for many patients this therapy isn't enough. And stepping back you realize that we have been driving these CAR-T ...

The χ 2 test, or Fisher's exact test if expected cell counts were less than five ... responses throughout an MI-E protocol in patients with ALS. Treatment failure with MI-E in patients with bulbar ...

As someone deeply immersed in the field of cell therapy, it thrills me to witness the rapid advancements that are pushing the boundaries of patient care further and faster than ever before.

Cell replacement for Parkinson's disease replaces the dopamine neurons lost to degeneration and can restore dopaminergic function in the brain, providing a completely new treatment modality ...

Cell replacement for Parkinson’s disease replaces the dopamine neurons lost to degeneration and can restore dopaminergic function in the brain, providing a completely new treatment modality ...

In particular, the therapy was found to significantly reduce the spread of toxic TDP-43 protein clumps, which form in the nerve cells of most ALS patients. The clumps can spread from one cell to ...